Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SynAct Pharma AB ( (SE:SYNACT) ) has provided an announcement.
SynAct Pharma AB announced its participation in the BioEurope 2025 conference in Vienna, a major event for the life sciences sector with over 5,700 delegates. The company aims to discuss potential collaborations for its lead program, Resomelagon, a non-suppressive immune modulation therapy for rheumatoid arthritis and inflammation due to viral infections, highlighting its potential to support millions of patients.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company specializing in the resolution of inflammation through the selective activation of the melanocortin system. The company offers a range of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, helping patients achieve immune balance.
Average Trading Volume: 182,611
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.23B
For detailed information about SYNACT stock, go to TipRanks’ Stock Analysis page.